Advances in antiplatelet therapy

Expert Opinion on Emerging Drugs

Volumn 8, Issue 2, 2003, Pages 349-363

  Jneid, Hani ^b   Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Acute coronary syndrome; Inflammation; Myocardial infarction; Percutaneous coronary infection; Peripheral arterial disease; Platelet; Stroke; Thrombosis

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTITHROMBOCYTIC AGENT; AR C 69931 MX; ATORVASTATIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; NM 702; PAMICOGREL; PHOSPHODIESTERASE V INHIBITOR; PRAVASTATIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PURINE ANTAGONIST; RIDOGREL; STATINE DERIVATIVE; STREPTOKINASE; TERBOGREL; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; WARFARIN; YM 337; Z 335;

ANTIINFLAMMATORY ACTIVITY; ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG POTENCY; DRUG TARGETING; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; LEG PAIN; META ANALYSIS; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENOMICS; POLYPHARMACY; REVIEW; RISK BENEFIT ANALYSIS; STROKE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIC PURPURA; THROMBOSIS; TREATMENT OUTCOME;

ADENOSINE DIPHOSPHATE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOXANE A2;

EID: 0345735897     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.2.349     Document Type: Review

References (138)

1. BADIMON JJ, ZAMAN A, HELFT G, FAYAD Z, FUSTER V: Acute coronary syndromes: pathophysiology and preventive priorities. Thromb. Haemost. (1999) 82:997-1004.
2. FUSTER V, FAYAD ZA, BADIMON JJ: Acute coronary syndromes: biology. Lancet (1999) 353(Suppl. 2):SII5-SII9.
3. CRIQUI MH, FRONEK A, BARRETT-CONNOR E, KLAUBER MR, GABRIEL S, GOODMAN D: The prevalence of peripheral arterial disease in a defined population. Circulation (1985) 71:510-515.
4. CRIQUI MH, LANGER RD, FRONEK A et al.: Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med. (1992) 326:381-386.
5. GOLDHABER SZ, MANSON JE, STAMPFER MJ et al.: Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet (1992) 340:143-145.
6. BROTT T, BOGOUSSLAVSKY J: Treatment of acute ischemic stroke. N. Engl. J. Med. (2000) 343:710-722.
7. INTERNATIONAL STROKE TRIAL COLLABORATIVE GROUP: The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet (1997) 349:1569-1581.
8. CAST (CHINESE ACUTE STROKE TRIAL) COLLABORATIVE GROUP: CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet (1997) 349:1641-1649.
9. DIENER HC, CUNHA L, FORBES C, SIVENIUS J, SMETS P, LOWENTHAL A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sc. (1996) 143:1-13.
10. CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348:1329-1339. The first randomised study comparing clopidrogel with aspirin in patients with CVD.
11. ROSS R: Atherosclerosis-an inflammatory disease. N. Engl. J. Med. (1999) 340:115-126. A comprehensive review of atherosclerosis and the role of inflammation in its pathogenesis.
12. BHATT DL, TOPOL EJ: Need to test the arterial inflammation hypothesis. Circulation (2002) 106:136-140.
13. BHATT DL, TOPOL EJ: Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. Drug Discov. (2003) 2:15-28. An updated and comprehensive review of antiplatelet therapy.
14. JNEID H, CORTI R, HUTTER R, ZAFAR U, FUSTER V, BADIMON JJ: The interplay between inflammation and thrombosis in atherosclerosis. Acute Coronary Syndromes (2002) 4:71-79. An updated review on atherosclerosis with emphasis on the role of thrombosis and inflammation and their interplay in its pathogenesis.
15. TOPOL EJ, SERRUYS PW: Frontiers in interventional cardiology. Circulation (1998) 98:1802-1820.
16. YUSUF S, REDDY S, OUNPUU S, ANAND S: Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation (2001) 104:2855-2864.
17. YUSUF S, REDDY S, OUNPUU S, ANAND S: Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation (2001) 104:2746-2753.
18. COOPER R, CUTLER J, DESVIGNE-NICKENS P et al.: Trends and disparities in coronary heart disease stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation (2000) 102:3137-3147.
19. JNEID H, BHATT DL, CORTI R, BADIMON JJ, FUSTER V, FRANCIS GS: Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch. Intern Med. (2003) 163:1145-1153.
20. GUM PA, KOTTKE-MARCHANT K, POGGIO ED et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. (2001) 88:230-235.
21. TEO KK, YUSUF S, PFEFFER M et al.: Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet (2002) 360:1037-1043.
22. CATELLA-LAWSON F, REILLY MP, KAPOOR SC et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. (2001) 345:1809-1817.
23. MACDONALD TM, WEI L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet (2003) 361:573-574.
24. COMMITTEE ON QUALITY OF HEALTH CARE IN AMERICA IOM: Crossing the quality chasm: a new health system for the 21st century. Washington, DC. National Academy Press (2001).
25. STEINHUBL SR, BERGER PB, MANN JT 3RD et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 288:2411-2420. The first randomised study demonstrating benefit from prolonged treatment with the combination of aspirin and clopidogrel over aspirin alone after PCIs.
26. YUSUF S, ZHAO F, MEHTA SR, CHROLAVICIUS S, TOGNONI G, FOX KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345:494-502. The first randomised study demonstrating benefit from prolonged treatment with the combination of aspirin and clopidogrel over aspirin alone after acute non-ST segment elevation coronary syndromes.
27. CALIFF RM, DELONG ER, OSTBYE T et al.: Underuse of aspirin in a referral population with documented coronary artery disease. Am. J. Cardiol. (2002) 89:653-661.
28. STAFFORD RS: Aspirin use is low among United States outpatients with coronary artery disease. Circulation (2000) 101:1097-1101.
29. DE REYNAL BF: [Aspirin still stands]. J. Belge. Rhumatol. Med Phys. (1965) 20:197-204.
30. CRAVEN L: Experiences with aspirin (acetylsalicyclic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss. Valley Med. J. (1953) 75:38-40.
31. WEISS HJ, ALEDORT LM: Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet (1967) 2:495-497.
32. VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. (1971) 231:232-235.
33. STEERING COMMITTEE OF THE PHYSICIANS' HEALTH STUDY RESEARCH GROUP: Final report on the aspirin component of the ongoing Physicians' Health Study: SCotPHSR. N. Engl. J. Med. (1989) 321(3):129-135. A large randomised study demonstrating the benefits of aspirin in primary prevention of CAD.
34. MANSON JE, STAMPFER MJ, COLDITZ GA et al.: A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA (1991) 266:521-527.
35. ISIS-2 (SECOND INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet (1988) 2:349-360. A large randomised study demonstrating the short-term and additive benefits of aspirin and thrombolytic therapy in acute MI.
36. ANTIPLATELET TRIALISTS' COLLABORATION: Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. (1994) 308:81-106.
37. ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324:71-86. A recent meta-analysis of all randomised trials of antiplatelet therapy in high-risk patients with CVD.
38. RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. (1997) 336:973-979.
39. ALEXANDER JH, HARRINGTON RA, TUTTLI RH et al.: Prior aspirin use predicts worse outcomes in patients with non-ST- elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am. J. Cardiol. (1999) 83:1147-1151.
40. EIKELBOOM JW, HIRSH J, WEITZ JI, JOHNSTON M, YI Q, YUSUF S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 105:1650-1655.
41. WALTER DH, SCRACHINGER V, ELSNER M, DIMMELER S, ZEIHER AM: Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet (1997) 350:1217-1219.
42. RIDKER PM, HENNEKENS CH, SCHMITZ C, STAMPFER MJ, LINDPAINTNER K: PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet (1997) 349:385-388.
43. SZCZEKLIK A, UNDAS A, SANAK M, FROLOW M, WEGRZYN W: Relationship between bleeding time, aspirin and the PIA1/A2 polymorphism of platelet glycoprotein IIIa. Br. J. Haematol. (2000) 110:965-967.
44. BHATT DL, TOPOL EJ: Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. Drug Discov. (2003) 2(1):15-28.
45. DE CLERCK F, BEETENS J, VAN DE WATER A, VERCAMMEN E, JANSSEN PA: R 68 070: Thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule-II. Pharmacological effects in vivo and ex vivo. Thromb. Haemost. (1989) 61:43-49.
46. DE CLERCK F, BEETENS J, DE CHAFFOY DE COURCELLES D, FREYNE E, JANSSEN PA: R 68 070: Thromboxane A2 synthetase inhibition and thromboxane A2/ prostaglandin endoperoxide receptor blockade combined in one molecule-I. Biochemical profile in vitro. Thromb. Haemost. (1989) 61:35-42.
47. SOYKA R, GUTH BD, WEISENBERGER HM, LUGER P, MULLER TH: Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors. J. Med. Chem. (1999) 42:1235-1249.
48. WATTS IS, WHARTON KA, WHITE BP, LUMLEY P: Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Br. J. Pharmacol. (1991) 102:497-505.
49. VANDEPLASSCHE G, HEMANS C, VAN DE WATER A et al.: Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries. Circ. Res. (1991) 69:313-324.
50. MUCK S, WEBER AA, SCHROR K: Effects of terbogrel on platelet inhibition and prostaglandin endoperoxide transfer. Eur. J. Pharmacol. (1998) 344:45-48.
51. THE RIDOGREL VERSUS ASPIRIN PATENCY TRIAL (RAPT): Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation (1994) 89:588-595.
52. TRANCHESI B, PILEGGI F, VERCAMMEN E, VAN DE WERF F, VERSTRAETE M: Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin. Eur. Heart J. (1994) 15:660-664.
53. LANGLEBEN D, CHRISTMAN BW, BARST RJ et al.: Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am. Heart J. (2002) 143:E4.
54. NAPOLI C, ACKAH E, DE NIGRIS F et al.: Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Proc. Natl. Acad. Sci. USA (2002) 99:12467-12470.
55. NAPOLI C, CIRINO G, DEL SOLDATO P et al.: Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc. Natl. Acad. Sci. USA (2001) 98:2860-2864.
56. NAPOLI C, ALDINI G, WALLACE JL et al.: Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc. Natl. Acad. Sci. USA (2002) 99:1689-1694.
57. GENT M, BLAKELY JA, EASTON JD et al.: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet (1989) 1:1215-1220.
58. BALSANO F, RIZZON P, VIOLI F et al.: Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation (1990) 82:17-26.
59. HALL P, NAKAMURA S, MAIELLO L et al.: A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound- guided stent implantation. Circulation (1996) 93:215-222.
60. STEINHUBL SR, TAN WA, FOODY JM, TOPOL EJ: Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA (1999) 281:806-810.
61. HELFT G, OSENDE JI, WORTHLEY SG et al.: Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler. Thromb. Vasc. Biol. (2000) 20:2316-2321.
62. BENNETT CL, CONNORS JM, CARWILE JM et al.: Thrombotic thrombocytopenic purpura associated with clopidogrel. N. Engl. J. Med. (2000) 342:1773-1777.
63. BHATT DL, HIRSCH AT, RINGLEB PA, HACKE W, TOPOL EJ: Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am. Heart J. (2000) 140:67-73.
64. BHATT DL, CHEW DP, HIRSCH AT, RINGLEB PA, HACKE W, TOPOL EJ: Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation (2001) 103:363-368.
65. HERBERT JM, DOL F, BERNAT A, FALOTICO R, LALE A, SAVI P: The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb. Haemost. (1998) 80:512-518.
66. BOSSAVY JP, THALAMAS C, SAGNARD L et al.: A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood (1998) 92:1518-1525.
67. MAKKAR RR, EIGLER NL, KAUL S et al.: Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur. Heart J. (1998) 19:1538-1546.
68. BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation (2002) 106:1893-1900. Updated guidelines for the management of patients with acute non-ST segment elevation coronary syndromes.
69. MEHTA SR, YUSUF S, PETERS RJ et al.: Effects of pretreatment with clopidogrel and aspirin followed by long- term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358:527-533.
70. BHATT DL, KAPADIA SR, BAJZER CT et al.: Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J. Invasive Cardiol. (2001) 13:767-771.
71. BHATT DL, BERTRAND ME, BERGER PB et al.: Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. Cardiol. (2002) 39:9-14. A meta-analysis of all studies comparing clopidogrel with ticlopidine after stenting during PCI procedures.
72. CHEW DP, BHATT DL, ROBBINS MA et al.: Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am. J. Cardiol. (2001) 88:672-674.
73. STOREY RF, JUDGE HM, WILCOX RG, HEPTINSTALL S: Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb. Haemost. (2002) 88:488-494.
74. PEARSON TA, MENSAH GA, ALEXANDER RW et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the american heart association. Circulation (2003) 107:499-511.
75. RIDKER PM, RIFAI N, CLEARFIELD M et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. (2001) 344:1959-1965.
76. LAU WC, WASKELL LA, WATKINS PB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 107:32-37.
77. SEREBRUANY VL, STEINHUBL SR, HENNEKENS CH: Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation (2003) 107:1568-1569.
78. HOLLOPETER G, JANTZEN HM, VINCENT D et al.: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature (2001) 409:202-207.
79. STOREY F: The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets (2001) 12:197-209.
80. STOREY RF, WILCOX RG, HEPTINSTALL S: Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets (2002) 13:407-413.
81. COLLER BS: Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation (1995) 92:2373-2380.
82. COLLER BS: A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J. Clin. Invest. (1985) 76:101-108.
83. THE EPIC INVESTIGATION: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. (1994) 330:956-961. The first randomised study demonstrating the benefits of GP IIb/IIIa receptor blockers (abciximab) during PCIs.
84. TOPOL EJ, CALIFF RM, WEISMAN HF et al.: Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet (1994) 343:881-886.
85. NANNIZZI-ALAIMO L, ALVES VL, PHILLIPS DR: Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation (2003) 107:1123-1128.
86. HENN V, SLUPSKY JR, GRAFE M et al.: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature (1998) 391:591-594. An original article demonstrating the role of CD40 ligand in vascular inflammation.
87. SLUPSKY JR, KALBAS M, WILLUWEIT A, HENN V, KROCZEK RA, MULLER-BERGHAUS G: Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb. Haemost. (1998) 80:1008-1014.
88. URBICH C, DERNBACH E, AICHER A, ZEIHER AM, DIMMELER S: CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation (2002) 106:981-986.
89. HEESCHEN C, DIMMELER S, HAMM CW et al.: Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. (2003) 348:1104-1111.
90. SCHONBECK U, VARO N, LIBBY P, BURING J, RIDKER PM: Soluble CD40L and cardiovascular risk in women. Circulation (2001) 104:2266-2268.
91. THE EPISTENT INVESTIGATORS: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet (1998) 352:87-92.
92. SMITH SC JR, DOVE JT, JACOBS AK et al.: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation (2001) 103:3019-3041.
93. ABDELMEGUID AE, TOPOL EJ, WHITLOW PL, SAPP SK, ELLIS SG: Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation (1996) 94:1528-1536.
94. KONG TQ, DAVIDSON CJ, MEYERS SN, TAUKE JT, PARKER MA, BONOW RO: Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA (1997) 277:461-466.
95. TOPOL EJ, MARK DB, LINCOFF AM et al.: Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet (1999) 354:2019-2024.
96. TOPOL EJ, LINCOFF AM, KEREIAKES DJ et al.: Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am. J. Med. (2002) 113:1-6.
97. LINCOFF AM, KEREIAKES DJ, MASCELLI MA et al.: Abciximab suppresses the rise in levels of circulating inflammatory markets after percutaneous coronary revascularization. Circulation (2001) 104:163-167.
98. BHATT DL, MARSO SP, LINCOFF AM, WOLSKI KE, ELLIS SG, TOPOL EJ: Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J. Am. Coll. Cardiol. (2000) 35:922-928. A pooled analysis of three clinical trials of abciximab in PCIs demonstrating its survival benefit in diabetic patients.
99. INVESTIGATORS TAIIS: Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke (2000) 31:2526-2527.
100. LEE DH, JO KD, KIM HG et al.: Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J. Vasc. Interv. Radiol. (2002) 13:769-774.
101. PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT IN PATIENTS LIMITED BY UNSTABLE SIGNS AND SYMPTOMS (PRISM-PLUS) STUDY INVESTIGATORS: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl. J. Med. (1998) 338:1488-1497.
102. THE PURSUIT TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N. Engl. J. Med. (1998) 339:436-443.
103. BOERSMA E, HARRINGTON RA, MOLITERNO DJ et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 359:189-198. A meta-analysis of the six Large randomised trials of GP IIb/IIIa receptor inhibitors in acute non-ST segment elevation coronary syndromes.
104. SIMOONS ML: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet (2001) 357:1915-1924.
105. THE PARAGON INVESTIGATORS: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation (1998) 97:2386-2395.
106. NEWBY LK, OHMAN EM, CHRISTENSON RH et al.: Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation (2001) 103:2891-2896.
107. QUINN MJ, BYZOVA TV, QIN J, TOPOL EJ, PLOW EF: Integrin {alpha}IIb{beta} 3 and its antagonism. Arterioscler. Thromb. Vasc. Biol. (2003) 23(6):945-952.
108. CHEW DP, BHATT DL, SAPP S, TOPOL EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of Phase III multicenter randomized trials. Circulation (2001) 103:201-206.
109. TOPOL EJ: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet (2001) 357:1905-1914.
110. ASSESSMENT OF THE SAFETY AND EFFICACY OF A NEW THROMBOLYTIC REGIMEN (ASSENT)-3 INVESTIGATORS: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358:605-613.
111. COVIC L, GRESSER AL, TALAVERA J, SWIFT S, KULIOPULOS A: Activation and inhibition of G protein-coupled receptors by cell- penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. USA (2002) 99:643-648.
112. AIKAWA M, RABKIN E, SUGIYAMA S et al.: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation (2001) 103:276-283.
113. ANDERLUH M, DOLENC MS: Thrombin receptor antagonists; recent advances in PAR-1 antagonist development. Curr. Med. Chem. (2002) 9:1229-1250.
114. SAMBRANO GR, WEISS EJ, ZHENG YW, HUANG W, COUGHLIN SR: Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature (2001) 413:74-78.
115. KAHN ML, NAKANISHI-MATSUI M, SHAPIRO MJ, ISHIHARA H, COUGHLIN SR: Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. (1999) 103:879-887.
116. KAGEYAMA S, YAMAMOTO H, YOSHIMOTO R: Anti-human von willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. Arterioscler. Thromb. Vasc. Biol. (2000) 20:2303-2308.
117. CAUWENBERGHS N, MEIRING M, VAUTERIN S et al.: Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler. Thromb. Vasc. Biol. (2000) 20:1347-1353.
118. LI Z, KIM ES, BEARER EL: Arp2/3 complex is required for actin polymerization during platelet shape change. Blood (2002) 99:4466-4474.
119. KONSTANTINIDES S, SCHAFER K, LOSKUTOFF DJ: The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity. Ann. NY Acad. Sci. (2001) 947:134-141; discussion 141-142.
120. KONSTANTINIDES S, SCHAFER K, KOSCHNICK S, LOSKUTOFF DJ: Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J. Clin. Invest. (2001) 108:1533-1540. An original article demonstrating the prothrombotic effects of leptin and its role in atherothrombosis.
121. BODARY PF, WESTRICK RJ, WICKENHEISER KJ, SHEN Y, EITZMAN DT: Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA (2002) 287:1706-1709.
122. KANEIDER NC, EGGER P, DUNZENDORFER S et al.: Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism. Arterioscler. Thromb. Vasc. Biol. (2002) 22:894-900.
123. ENJYOJI K, SEVIGNY J, LIN Y et al.: Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat. Med. (1999) 5:1010-1017.
124. PINSKY DJ, BROEKMAN MJ, PESCHON JJ et al.: Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J. Clin. Invest. (2002) 109:1031-1040.
125. FIORUCCI S, ANTONELLI E, DISTRUTTI E et al.: NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc. Natl. Acad. Sci. USA (2002) 99:15770-15775.
126. FIORUCCI S, MENCARELLI A, MENEGUZZI A et al.: NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation (2002) 106:3120-3125.
127. FIORUCCI S, SANTUCCI L, GRESELE P, FACCINO RM, DEL SOLDATO P, MORELLI A: Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology (2003) 124:600-607.
128. WAINWRIGHT CL, MILLER AM, WORK LM, DEL SOLDATO P: NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. Br. J. Pharmacol. (2002) 135:1882-1888.
129. SHUKLA N, ANGELINI GD, ASCIONE R, TALPAHEWA S, CAPOUN R, JEREMY JY: Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure. Am. Thorac. Surg. (2003) 75:1437-1442.
130. DICKFELD T, RUF A, POGATSA-MURRAY G et al.: Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists. Thromb. Res. (2001) 101:53-64.
131. KUWAHARA M, SUGIMOTO M, TSUJI S et al.: Comparative studies on the antiplatelet effects of a humanized antiplatelet glycoprotein IIb/IIIa antibody (YM337) and ReoPro under flow conditions. Thromb. Haemost. (1998) 80:28-31.
132. KAMATH S, LIP GY: YM-337. Yamanouchi. Curr. Opin. Investig. Drugs (2001) 2:1093-1096.
133. TANAKA T, FUKUTA Y, HIGASHINO R et al.: Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist. Eur. J. Pharmacol. (1998) 357:53-60.
134. TANAKA T, SATO R, KURIMOTO T: Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats. Eur. J. Pharmacol. (2000) 401:413-418.
135. TANAKA T, FUKUTA Y, FUKUDA Y et al.: Z-335, a thromboxane A2 receptor antagonist, suppresses the progression of arachidonic acid-induced hind limb gangrene in rats. Biol. Pharm. Bull. (1999) 22:1382-1384.
136. HALPERIN JL: A long-term randomized trial comparing ximelagatran with warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (SPORTIF III). In: Annual Scientific Sessions - American College of Cardiology. Chicago (2003).
137. LINCOFF AM, BITTL JA, HARRINGTON RA et al.: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 289:853-863.
138. http://www.americanheart.com/presenter.jhtml?identifier=3000090 American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, Tex.: American Heart Association (2002).